Hashimoto's thyroiditis Hashimoto's thyroiditis is one of the more commonly discussed autoimmune conditions in the context of GLP-1 medications, partly because thyroid function monitoring is already recommended for tirzepatide users due to the medication boxed warning about medullary thyroid carcinoma risk
Heres how GLP-1 therapies impact multiple organ systems: GLP-1 therapies are associated with rapid reductions in cardiovascular events, which correlate with improvements in CRP levels
The company has, however, faced some significant challenges
Missing doses or varying injection timing by multiple days can reduce semaglutide's appetite-suppressing effect and increase rebound hunger during the gap
Commonly reported effects include nausea, vomiting, diarrhea, constipation, stomach discomfort, reduced appetite, headache, and fatigue
Pack Size: 30s